US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

223.00

-4.7500-2.09%

Post-market: 223.660.6600+0.30%19:57 EDT

Volume:804.93K

Turnover:174.45M

Market Cap:562.96M

PE:- -

High:224.85

Open:221.88

Low:208.28

Close:227.75

52wk High:341.93

52wk Low:102.35

Shares:2.52M

Float Shares:2.52M

Volume Ratio:1.53

T/O Rate:31.88%

Dividend:0.91

Dividend Rate:0.41%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway

BioNTech SE (BNTX) Gets a Buy from Morgan Stanley

Crescent Biopharma Receives FDA Clearance for Investigational New Drug Application

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Market Chatter: GE Healthcare to Acquire Sofie Biosciences in $945 Million Cash Deal

MT Newswires Live

EPF lifts stake in IHH Healthcare to over 13%

GE Healthcare to Buy Sofie Biosciences in $945 Million Cash Deal, WSJ Reports

MT Newswires Live

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Alvotech Gets US FDA Approval For Additional Manufacturing Capacity For Simlandi Biosimilar; Shares Up Pre-Bell

MT Newswires Live

Man Group PLC : Form 8.3 - Spire Healthcare Group Plc

Omega Healthcare to transition 32 facilities in Florida to Pacs Group

Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Shattuck Labs (STTK) and Arcus Biosciences (RCUS)

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

HanchorBio Secures US FDA Clearance for Solid Tumor Treatment

MT Newswires Live

Aurobindo Pharma Gets US FDA Approval for Perampanel Tablets

MT Newswires Live

Alignment Healthcare (ALHC) Could Be 64% Undervalued As Hoag Deal Expands Orange County Reach

Simply Wall St.

Sonic Healthcare's Funding Risk is Growing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LABU/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":223,"timestamp":1791489600000,"preClose":227.75,"halted":0,"volume":804929,"hourTrading":{"tag":"盘后","latestPrice":223.66,"preClose":223,"latestTime":"19:57 EDT","volume":4124,"amount":918785.7173,"timestamp":1791503872443,"change":0.66,"changeRate":0.00296,"amplitude":0.008427},"delay":0,"changeRate":-0.020856201975850714,"floatShares":2524486,"shares":2524486,"eps":0,"marketStatus":"Not Yet Opened","change":-4.75,"latestTime":"10-08 16:00:00 EDT","open":221.88,"high":224.8479,"low":208.28,"amount":174447835.0605,"amplitude":0.072746,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791532800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":227.75,"sharesOutstanding":3074486,"nav":227.52,"aum":597123938.28,"dividendRate":0.004085,"bidAskSpread":0.003146,"preHourTrading":{"tag":"盘前","latestPrice":220.18,"preClose":227.75,"latestTime":"09:29 EDT","volume":6169,"amount":1385605.45651,"timestamp":1791466199999,"change":-7.57,"changeRate":-0.033238,"amplitude":0.038727},"postHourTrading":{"tag":"盘后","latestPrice":223.66,"preClose":223,"latestTime":"19:57 EDT","volume":4124,"amount":918785.7173,"timestamp":1791503872443,"change":0.66,"changeRate":0.00296,"amplitude":0.008427},"volumeRatio":1.526101,"impliedVol":1.0277,"impliedVolPercentile":0.9004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2524486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.526101,"shares":2524486,"dividePrice":0.911,"high":224.8479,"amplitude":0.072746,"preClose":227.75,"low":208.28,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":223,"eps":0,"divideRate":0.004085,"volume":804929,"delay":0,"ttmEps":0,"open":221.88,"prevYearClose":159.39,"prevWeekClose":248.72,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":249.65,"twentyDayClose":266,"sixtyDayClose":277.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673970740","title":"Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2673970740","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673970740?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:45","pubTimestamp":1791204300,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, Oct.  05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374561/0/en/immix-biopharma-to-participate-in-the-45th-annual-j-p-morgan-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1989772923.USD","LU1244550577.SGD","LU2028103732.USD","IE00BZ1G4Q59.USD","XBI","ODD","LU0006306889.USD","BK4127","LU0795875086.SGD","LU0390134368.USD","LU1988902786.USD","LU2264538146.SGD","LU1162221912.USD","BK4581","BK4183","LU0128526141.USD","LU0106261372.USD","LU1989772840.SGD","LU1668664300.SGD","LU0528227936.USD","LU1244550494.USD","LU1548497426.USD","LU0106831901.USD","LU2111349929.HKD","LU1732800096.USD","LU0158827781.USD","LU0225283273.USD","LU0795875169.SGD","HCSG","XLV","LU1074936037.SGD","LU1064131342.USD","IE0009354923.USD","LU2089284900.SGD","BK4516","LU2487616109.SGD","LU2347655156.SGD","KBWB","LU2089283258.USD","LU1791710582.SGD","BK4534","LU2023251221.USD","LU1363072403.SGD","LU1791710400.SGD","LU1244550221.USD","LABU","BK4137","IAI","IE00B3S45H60.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673707408","title":"Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2673707408","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673707408?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:45","pubTimestamp":1791204300,"startTime":"0","endTime":"0","summary":"Companies to Meet Formally with FDA’s Center for Veterinary Medicine on November 19th for Pre-Submission Conference; U.S. Manufacturing Strategy Underway to Support Potential 2027 Veterinary Product L","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374563/0/en/endovia-and-lupvindol-biosciences-announce-fda-determination-that-cannepil-for-canine-bone-cancer-pain-qualifies-as-a-minor-use-establishing-eligibility-for-conditional-approval-pa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBD","BK4588","EES","LU0130103400.USD","LU1201861165.SGD","LU0963586101.USD","LU0648000940.SGD","LU2324357040.USD","LABU","BK4113","BK4585","BK4185","THC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673707907","title":"BioNTech SE (BNTX) Gets a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2673707907","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673707907?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:37","pubTimestamp":1791203873,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn assigned a Buy rating to BioNTech SE today and set a price target of $115.00. Flynn covers the Healthcare sect...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biontech-se-bntx-gets-a-buy-from-morgan-stanley-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biontech-se-bntx-gets-a-buy-from-morgan-stanley-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2177674079.SGD","SG9999014484.SGD","BK4566","LU2125910849.SGD","LU0572939691.SGD","IE0001KFT4U8.USD","FDNI","LU0499858438.USD","LU0516423091.SGD","SG9999002620.SGD","BK4139","LU0345775950.USD","BK4581","LU0516422366.SGD","BK4503","SG9999013478.USD","LU0072462343.USD","LU0589944569.HKD","SG9999002604.SGD","LU1861217088.USD","SG9999013486.USD","LU1861220207.SGD","IE0034224299.USD","XLV","LU2152927971.USD","LU0499858602.USD","XBI","LU0289960550.SGD","LU2125910500.SGD","BNTX","LU2008162690.USD","BK4551","LABU","SG9999002414.USD","LU0823039010.USD","BK4085","LU0175139822.USD","SE","LU0210637038.USD","LU2065169927.USD","LU1242518931.SGD","LU0048573645.USD","BK4548","LU0516422952.EUR","SG9999002406.SGD","LU0348788117.USD","SG9999002679.SGD","LU2065171402.SGD","LU0251143029.SGD","IE00BD6J9T35.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702048","title":"Crescent Biopharma Receives FDA Clearance for Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702048","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702048?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:15","pubTimestamp":1791202500,"startTime":"0","endTime":"0","summary":"Crescent Biopharma said the Food and Drug Administration cleared its investigational new drug application for CR-002 to treat advanced solid tumors.Chief Medical Officer Ellie Im on Monday said the clearance marks an important milestone for Crescent, as it means that the company can begin its trial--known as Apollo--for the drug.\"We look forward to initiating the Apollo trial this quarter and working with global investigators to generate important clinical insights and advance our mission of bringing new treatment options to patients living with difficult-to-treat cancers,\" Im said.Crescent plans to study the treatment in patients with advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and various gastrointestinal and gynecological tumors.Initial clinical data from the trial is expected to be reported in the second half of 2027, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","CBIO","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702726","title":"Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702726","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702726?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201600,"startTime":"0","endTime":"0","summary":"~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill platform technology ~SAN JOSE, Calif., Oct.  05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Na","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374470/0/en/rani-therapeutics-announces-acceptance-into-u-s-fda-s-emerging-technology-program-etp.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LENZ","BK4139","BK4539","LABU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702083","title":"Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702083","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702083?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201600,"startTime":"0","endTime":"0","summary":"Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374491/0/en/radiopharm-completes-productive-end-of-phase-2-meeting-with-u-s-food-and-drug-administration-for-pivotal-development-program-of-rad101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RADX","BK4585","BK4139","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673026877","title":"Market Chatter: GE Healthcare to Acquire Sofie Biosciences in $945 Million Cash Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673026877","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673026877?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:54","pubTimestamp":1791201294,"startTime":"0","endTime":"0","summary":"GE HealthCare Technologies  is expected to announce its acquisition of Sofie Biosciences, a manufacturer of radioactive substances used in medical-imaging procedures, for $945 million in cash, The Wall Street Journal reported Monday, citing the company.The medical-equipment maker will buy Sofie from private equity firm Trilantic North America, with the deal likely to be announced Monday, according to the report.GE HealthCare didn't immediately respond to MT Newswires' request for comment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","BK4581","XBI","BK4585","LU0124676726.USD","LU0029874061.USD","LU0128526141.USD","BK4082","BK4588","BK4137","LGHT","LABU","GEHC","HCSG","LU0689626769.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702621","title":"EPF lifts stake in IHH Healthcare to over 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702621","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702621?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:51","pubTimestamp":1791201090,"startTime":"0","endTime":"0","summary":"IHH Healthcare Bhd ( ($IHHHF) ) has issued an announcement. Malaysia’s Employees Provident Fund Board has increased its direct stake in IHH Healthc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/epf-lifts-stake-in-ihh-healthcare-to-over-13?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/epf-lifts-stake-in-ihh-healthcare-to-over-13?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4581","XBI","BK4585","LU0029874061.USD","LU0128526141.USD","BK4588","BK4137","LABU","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673470232","title":"GE Healthcare to Buy Sofie Biosciences in $945 Million Cash Deal, WSJ Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2673470232","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673470232?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:48","pubTimestamp":1791200885,"startTime":"0","endTime":"0","summary":"GE Healthcare to Buy Sofie Biosciences in $945 Million Cash Deal, WSJ Reports","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","HCSG","BK4588","BK4082","BK4137","GEHC","LABU","BK4581","LU0689626769.HKD","LU0124676726.USD","LU0029874061.USD","LGHT","LU0128526141.USD","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704061","title":"Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704061","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704061?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:30","pubTimestamp":1791199800,"startTime":"0","endTime":"0","summary":"Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to ini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374436/0/en/crescent-biopharma-announces-fda-clearance-of-ind-application-for-cr-002-a-pd-l1-targeted-topoisomerase-inhibitor-adc-for-the-treatment-of-solid-tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NETL","BK4080","BK4588","CR","LABU","BK4231","BK4585","ADC","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704113","title":"Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704113","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704113?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":"The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities On track to report topline resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374399/0/en/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LU2125154778.USD","LU0128526141.USD","BK4161","LU2360032135.SGD","LABU","LU2125154935.USD","HI","CHI","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673836709","title":"Alvotech Gets US FDA Approval For Additional Manufacturing Capacity For Simlandi Biosimilar; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2673836709","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673836709?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:52","pubTimestamp":1791193923,"startTime":"0","endTime":"0","summary":"Alvotech  has received US Food and Drug Administration approval for a supplement to the biologics license application for AVT02, marketed as Simlandi in the US, the company said Monday.The move allows drug substance for the product to be manufactured in a second production suite at the company's facility in Reykjavik, Iceland, and further confirms resolution of FDA inspection-related matters at the site.Simlandi is Alvotech's biosimilar to Humira.The company's shares were up 5.9% in premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LABU","BK4588","BK4585","ALVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673045706","title":"Man Group PLC : Form 8.3 - Spire Healthcare Group Plc","url":"https://stock-news.laohu8.com/highlight/detail?id=2673045706","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673045706?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:45","pubTimestamp":1791193500,"startTime":"0","endTime":"0","summary":"FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.KEY INFORMATION (a)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374276/0/en/man-group-plc-form-8-3-spire-healthcare-group-plc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4137","LABU","BK4581","LU0128526141.USD","LU0029874061.USD","BK4585","XLV","HCSG","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673067387","title":"Omega Healthcare to transition 32 facilities in Florida to Pacs Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2673067387","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673067387?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:30","pubTimestamp":1791192634,"startTime":"0","endTime":"0","summary":"Omega Healthcare (OHI) announced that it transitioned 32 skilled nursing facilities in Florida from an operator managed by affiliates of Airamid He...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omega-healthcare-to-transition-32-facilities-in-florida-to-pacs-group-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omega-healthcare-to-transition-32-facilities-in-florida-to-pacs-group-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4588","BK4585","SRET","BK4137","SRHR","REZ","BK4581","BK4225","XLV","BK4203","HCSG","OHI","LABU","LU0029874061.USD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673703019","title":"Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Shattuck Labs (STTK) and Arcus Biosciences (RCUS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673703019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673703019?lang=en_us&edition=fundamental","pubTime":"2026-10-05 16:10","pubTimestamp":1791187816,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Encompass Health (EHC), Shattuck Labs (STTK) and Arc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-encompass-health-ehc-shattuck-labs-sttk-and-arcus-biosciences-rcus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-encompass-health-ehc-shattuck-labs-sttk-and-arcus-biosciences-rcus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","SG9999004303.SGD","BK4588","BK4137","RCUS","LU1983260115.SGD","BK4585","BK4139","XLV","LABU","LU2237957902.USD","LU2237957811.SGD","STTK","BK4185","XBI","LU0054578231.USD","BK4581","HCSG","LU0029874061.USD","SGXZ23171101.USD","EHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673470582","title":"FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®","url":"https://stock-news.laohu8.com/highlight/detail?id=2673470582","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673470582?lang=en_us&edition=fundamental","pubTime":"2026-10-05 16:00","pubTimestamp":1791187200,"startTime":"0","endTime":"0","summary":"Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374199/0/en/fda-approves-additional-u-s-manufacturing-capacity-for-simlandi-alvotech-s-biosimilar-to-humira.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4166","ALVO","BBP","EES","MADE","LABU","BK4582","BK4588","GAST","VAI","BK4585","AMER","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673772375","title":"HanchorBio Secures US FDA Clearance for Solid Tumor Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673772375","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673772375?lang=en_us&edition=fundamental","pubTime":"2026-10-05 11:55","pubTimestamp":1791172541,"startTime":"0","endTime":"0","summary":"FBD Biologics, a subsidiary of HanchorBio (TPE:7827) has received U.S. Food and Drug Administration clearance for its Investigational New Drug application for HCB303, a trispecific fusion protein bein","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673977484","title":"Aurobindo Pharma Gets US FDA Approval for Perampanel Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2673977484","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673977484?lang=en_us&edition=fundamental","pubTime":"2026-10-05 10:37","pubTimestamp":1791167827,"startTime":"0","endTime":"0","summary":"Aurobindo Pharma  received final approval from the U.S. Food and Drug Administration to manufacture and market Perampanel Tablets in strengths ranging from 2 mg to 12 mg, according to an Oct. 3 exchange filing.The product will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary, and launched in the third quarter of fiscal 2027.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673774730","title":"Alignment Healthcare (ALHC) Could Be 64% Undervalued As Hoag Deal Expands Orange County Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2673774730","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673774730?lang=en_us&edition=fundamental","pubTime":"2026-10-05 08:19","pubTimestamp":1791159554,"startTime":"0","endTime":"0","summary":"Hoag partnership puts Alignment Healthcare’s Orange County reach in focus\nAlignment Healthcare (ALHC) just announced that its Alignment Health Plan will add Hoag to its network in Orange County, giving Medicare Advantage members in-network access starting January 1, 2027.\nThe agreement includes Hoag’s 1,800 physicians, two acute-care hospitals and a broad set of urgent care and outpatient facilities, tied to select offerings such as the new $0-premium Alignment Health Platinum Preferred HMO...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6034000-choice1-card/1789283981127","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6034000-choice1-card/1789283981127"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-alhc/alignment-healthcare/news/alignment-healthcare-alhc-could-be-64-undervalued-as-hoag-de","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-alhc/alignment-healthcare/news/alignment-healthcare-alhc-could-be-64-undervalued-as-hoag-de","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALHC","BK4588","BK4581","XLV","BK4585","BK4539","ICBK","BK4154","LABU","BK4211","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776104","title":"Sonic Healthcare's Funding Risk is Growing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776104","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776104?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:56","pubTimestamp":1791154560,"startTime":"0","endTime":"0","summary":"2256 GMT - Funding risk is growing for Sonic Healthcare, says UBS. \"While management has historically deemed U.S. and German funding reforms as unlikely, we believe growing policy momentum makes that view increasingly difficult to sustain,\" UBS says. In the U.S., PAMA reimbursement cuts have been proposed. These would reduce earnings by A$15 million, UBS says. In Germany, the local laboratory association has warned reforms could reduce private billing revenues by 34%. \"Notably, the debate has shifted from whether reform proceeds to how severe the impact will be,\" UBS says. \"We remain more optimistic than the industry's assumptions, modelling a 4% revenue headwind.\" Sonic ended last week at A$18.46. The stock is down 22% from its mid-August high.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4534","LU1863844665.USD","BK4585","LU1829250122.USD","LABU","BK7124","BK4588","LU3187612489.SGD","LU1863844749.USD","BK4118","SHL.AU","XBI","XLV","UBS","IE0034235071.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":9,"totalSize":427,"code":"91000000","status":"200"}]}}